Hinge Health (HNGE)
Market Price (2/16/2026): $39.0 | Market Cap: $3.1 BilSector: Health Care | Industry: Health Care Technology
Hinge Health (HNGE)
Market Price (2/16/2026): $39.0Market Cap: $3.1 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% | Weak multi-year price returns2Y Excs Rtn is -32%, 3Y Excs Rtn is -62% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -553 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -103% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 117% | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% | |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices. | Key risksHNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 27%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices. |
| Weak multi-year price returns2Y Excs Rtn is -32%, 3Y Excs Rtn is -62% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -553 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -103% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 117% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -22% |
| Key risksHNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Analyst Price Target Reductions and Cautious Outlook.
Despite reporting strong financial results for Q4 2025, several analysts revised down their price targets for Hinge Health (HNGE) during the period, signaling a more conservative valuation or outlook on future growth. For instance, Barclays cut its target from $60.00 to $52.00 on February 11, 2026, Piper Sandler lowered its target from $71.00 to $60.00 in January 2026, and Keybanc reduced its target from $72.00 to $70.00, also in January 2026. These adjustments, even with positive current performance, contributed to a bearish sentiment and downward pressure on the stock.
2. Broader Market Sentiment and Valuation Concerns for Growth Stocks.
Hinge Health's stock has faced ongoing pressure since its Initial Public Offering in May 2025, often trading near its 52-week low despite generally supportive analyst ratings. The company appears to have been impacted by broader investor rotations away from high-growth, technology-enabled healthcare companies, particularly those that may not yet consistently demonstrate GAAP profitability. Although Hinge Health achieved GAAP profitability in Q4 2025, it still reported a full-year loss for 2025, which likely contributed to investor caution regarding its long-term valuation and sustained profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -21.7% change in HNGE stock from 10/31/2025 to 2/15/2026 was primarily driven by a -26.0% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 49.76 | 38.94 | -21.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 335 | 355 | 5.7% |
| P/S Multiple | 10.2 | 7.5 | -26.0% |
| Shares Outstanding (Mil) | 69 | 69 | 0.0% |
| Cumulative Contribution | -21.7% |
Market Drivers
10/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| HNGE | -21.7% | |
| Market (SPY) | -0.0% | 11.2% |
| Sector (XLV) | 9.3% | 7.3% |
Fundamental Drivers
The -13.4% change in HNGE stock from 7/31/2025 to 2/15/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 44.95 | 38.94 | -13.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 355 | 0.0% |
| P/S Multiple | � | 7.5 | 0.0% |
| Shares Outstanding (Mil) | 69 | 69 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| HNGE | -13.4% | |
| Market (SPY) | 8.2% | 21.6% |
| Sector (XLV) | 21.4% | 3.1% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| HNGE | ||
| Market (SPY) | 14.3% | 22.5% |
| Sector (XLV) | 8.8% | 1.9% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/15/2026| Return | Correlation | |
|---|---|---|
| HNGE | ||
| Market (SPY) | 74.0% | 22.5% |
| Sector (XLV) | 23.7% | 1.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HNGE Return | - | - | - | - | 24% | -15% | 5% |
| Peers Return | -46% | -65% | -39% | -63% | -28% | -16% | -97% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| HNGE Win Rate | - | - | - | - | 50% | 50% | |
| Peers Win Rate | 31% | 25% | 44% | 33% | 28% | 17% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HNGE Max Drawdown | - | - | - | - | -7% | -33% | |
| Peers Max Drawdown | -53% | -68% | -59% | -71% | -58% | -21% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, AMWL, DRIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to TDOC, AMWL, DRIO
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Hinge Health (HNGE)
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Hinge Health:
- Peloton for physical therapy and musculoskeletal health: Hinge Health brings guided exercise programs and coaching for back and joint pain directly into people's homes, similar to how Peloton provides fitness classes.
- Teladoc for chronic back and joint pain: Hinge Health offers specialized virtual care, including physical therapy and health coaching, specifically for musculoskeletal conditions, much like Teladoc provides general virtual doctor visits.
AI Analysis | Feedback
- Digital Musculoskeletal (MSK) Program: Provides virtual physical therapy, health coaching, and educational content for individuals experiencing chronic or acute joint and muscle pain.
- Preventive MSK Program: Offers personalized exercise routines and educational resources designed to help individuals prevent the onset or worsening of musculoskeletal conditions.
- Surgical Pathway Program: Delivers pre-operative and post-operative support, including personalized exercise plans and guidance, for members undergoing musculoskeletal surgery.
- Women's Pelvic Health Program: A specialized virtual program offering exercises and coaching to address conditions related to pelvic floor dysfunction, such as incontinence or pelvic pain.
AI Analysis | Feedback
Hinge Health (symbol: HNGE) primarily sells its digital musculoskeletal (MSK) solutions to other companies (B2B).
While Hinge Health serves a broad base of over 1,500 customers and does not typically disclose specific "major customers" by name in its public filings (as no single customer accounts for a material portion of its revenue), their customer base consists primarily of two categories of large organizations:
-
Large Employers: Hinge Health partners with a significant portion of the Fortune 500, including 96% of these companies. These customers are diverse across various industries, offering Hinge Health's solutions as an employee benefit. While specific names of individual major customers are not disclosed by Hinge Health, examples of companies within the Fortune 500 that represent their target client base include:
- Walmart (WMT)
- Amazon (AMZN)
- Apple (AAPL)
- Microsoft (MSFT)
- Alphabet (GOOGL)
-
Major Health Plans: Hinge Health works with some of the largest health plans in the United States, including 11 of the top 15. These health plans often offer Hinge Health's solutions to their members or through employer benefit programs. Examples of such major health plans that are public companies include:
- UnitedHealth Group (UNH)
- Elevance Health (ELV)
- Cigna Group (CI)
- CVS Health (CVS) (which includes Aetna)
AI Analysis | Feedback
- Amazon.com, Inc. (AMZN) - for Amazon Web Services (AWS)
AI Analysis | Feedback
Daniel Perez, Chief Executive Officer
Daniel Perez co-founded Hinge Health in 2014, inspired by his personal experiences with musculoskeletal injuries. He holds a B.S. in Biology from Westminster University and attended a DPhil (PhD) program in biochemistry at Oxford University. Prior to Hinge Health, he co-founded Marblar in 2011 and the Oxbridge Biotech Roundtable, and Hinge Health is the third company he and Gabriel Mecklenburg have co-founded and run together. Under his leadership, Hinge Health has treated over 1.5 million people and raised over $800M in venture financing before going public.
James Budge, Chief Financial Officer
James Budge has served as the Chief Financial Officer of Hinge Health since March 2023. He previously held CFO positions at Automation Anywhere, Pluralsight, and Anaplan. Before these roles, he was the Chief Financial Officer and Chief Operating Officer at Genesys Cloud Services and Rovi Corporation. Mr. Budge holds a B.S. in Accounting from Brigham Young University.
Gabriel Mecklenburg, Executive Chairman
Gabriel Mecklenburg co-founded Hinge Health in 2014 with Daniel Perez. He also served as the company's Chief Operating Officer from October 2014 to February 2021. He was previously the Chief Operating Officer at Oxbridge Biotech Roundtable Ltd. and co-founded Marblar, a product development company focused on healthcare. Mr. Mecklenburg holds an M.Sc. in Materials Science from the University of Cambridge and an M.Phil. in Bioengineering from Imperial College London. He also serves on the board of directors of Pelago Health.
Jim Pursley, President
Jim Pursley has served as President of Hinge Health since March 2021. Before joining Hinge Health, he was the Chief Commercial Officer for Livongo Health, where he was part of the founding executive team that took the company public in 2019, ultimately leading to an $18.5 billion acquisition by Teladoc Health. He also held various executive roles at Care Innovations and GE HealthCare Technologies. Mr. Pursley earned an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from Pennsylvania State University.
Dr. Jeffrey Krauss, Chief Medical Officer
Dr. Jeffrey Krauss joined Hinge Health as Chief Medical Officer in September 2018. He graduated from Harvard College, received his medical degree from the UC San Francisco School of Medicine, and completed his residency in physical medicine and rehabilitation (PM&R) at Stanford University. He is board-certified in PM&R and Lifestyle Medicine and is a clinical assistant professor at Stanford. Before his medical career, Dr. Krauss worked in product management for eight years at eBay and Oracle.
AI Analysis | Feedback
Hinge Health (NYSE: HNGE) faces several key risks to its business as a publicly traded company in the digital musculoskeletal (MSK) care market.Key Risks to Hinge Health's Business
1. Intense Competitive Pressures and Market Commoditization: Hinge Health operates in a highly competitive digital MSK care market, facing rivals such as Omada Health, Sword Health, and Kaia Health, as well as traditional healthcare providers developing similar solutions. This intense competition can lead to increased pricing pressure, heightened customer expectations, and challenges in maintaining client retention and differentiation. The potential for commoditization of digital MSK programs, especially in cost-cutting environments, poses a significant threat to Hinge Health's premium pricing position, as its technological advantages in AI-powered motion tracking could be replicated by competitors.
2. Profitability Concerns and High Valuation: Despite demonstrating robust revenue growth, Hinge Health has reported GAAP losses, which have been influenced by substantial stock-based compensation. These ongoing losses raise concerns about long-term profitability and potential shareholder dilution. The company's elevated forward Price/Book multiple, significantly higher than industry averages, suggests that investors have high expectations for future growth and profitability. Any deceleration in revenue growth or difficulties in expanding beyond its core MSK offerings could lead to a sharp repricing of the stock, impacting investor confidence.
3. Regulatory and Data Privacy Risks: Operating within the heavily regulated healthcare sector, Hinge Health is exposed to significant regulatory and legal challenges, particularly concerning data privacy and the use of artificial intelligence in healthcare. Compliance with evolving regulations, such as those related to data protection (e.g., HIPAA), could incur substantial costs and operational complexities, potentially impacting the company's financial performance and operational efficiency. Increased regulatory scrutiny of AI in healthcare also presents an ongoing risk.
AI Analysis | Feedback
The increasing demand from employers and health plans for consolidated, integrated digital health platforms that address multiple chronic conditions (e.g., musculoskeletal, diabetes, hypertension, mental health) rather than individual point solutions. This trend pressures Hinge Health, historically a leading point solution for musculoskeletal care, to rapidly expand its scope or risk being at a disadvantage compared to competitors (such as Omada Health, DarioHealth, or even larger telehealth providers) that offer broader, bundled solutions. This also makes Hinge Health vulnerable to employers and payers opting to partner with fewer, more comprehensive vendors to reduce "vendor fatigue" and streamline benefits management.
AI Analysis | Feedback
Hinge Health primarily offers a digital clinic for musculoskeletal (MSK) care, providing personalized online physical therapy programs, AI-powered motion tracking, and access to physical therapists and health coaches. They also provide an FDA-cleared wearable device called Enso for pain relief. Hinge Health targets self-insured employers and health plans.
The addressable markets for Hinge Health's main products and services are significant:
-
The total musculoskeletal (MSK) care burden in the U.S. is estimated at $1.3 trillion annually, comprising $661 billion in direct spend and an additional $624 billion in indirect costs.
-
Within the broader digital health for musculoskeletal care market, the global market size was estimated at approximately $4.44 billion in 2024 and is projected to reach $11.64 billion by 2030, with a compound annual growth rate (CAGR) of 17.7% from 2025 to 2030.
-
Focusing on the U.S., the digital health for musculoskeletal care market generated an estimated revenue of $1.30 billion in 2024 and is expected to grow to $3.09 billion by 2030, at a CAGR of 15.5% from 2025 to 2030. The U.S. accounted for 29.4% of the global digital health for musculoskeletal care market in 2024.
-
Hinge Health's specific addressable market within the U.S. includes its current self-insured employer market, which represents an approximate $10 billion opportunity.
-
Adjacent market opportunities in the U.S. include fully-insured employers and Medicare Advantage plans, which constitute an $8 billion addressable market with 96 million additional lives, and government agencies and healthcare programs (Medicare/Medicaid), offering another $9 billion opportunity with 112 million lives.
-
Physical therapy, a core service for Hinge Health, represents a $60 billion-plus market in the United States, despite being only 1.2% of total healthcare spending.
AI Analysis | Feedback
Hinge Health (HNGE) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Growth in Client Base and Member Enrollment: Hinge Health's revenue model is directly tied to the number of eligible lives and the percentage of those who enroll and engage with their programs (yield). The company has consistently expanded its client base, including large employers, and focuses on increasing eligible lives through new client acquisitions and further penetration within existing accounts. This continued expansion of clients and successful enrollment initiatives are crucial for revenue growth.
- Expansion into New Markets: The company is actively diversifying its revenue streams beyond its core self-insured employer market. This includes strategic expansion into fully-insured health plans, Medicare Advantage, and global markets. For example, Hinge Health began international expansion in Canada in Q3 2024 and plans European launches for 2025, which will open up significant new revenue opportunities.
- New Product and Service Innovation, particularly AI-Powered Offerings: Hinge Health is continually investing in research and development to launch new products and enhance existing services. Key initiatives include its AI-powered platform for automated care delivery, such as the AI care assistant "Robin" and advanced motion analysis capabilities, which improve efficiency and outcomes. Additionally, the launch of HingeSelect, a network of in-person providers, is designed to offer a more comprehensive musculoskeletal (MSK) care model and tap into new patient segments. The company is also exploring new focus areas beyond MSK, such as women's health.
- Leveraging an Engagement-Based Pricing Model and Improved Operational Efficiency: Hinge Health's revenue model incorporates an engagement-based pricing structure, where clients pay for members who actively engage. The company's AI-driven platform significantly improves operational efficiency, leading to higher gross margins and the ability to scale its technology-driven care model more effectively. This scalability and focus on engagement ensure that revenue growth is supported by efficient service delivery and strong member utilization.
AI Analysis | Feedback
Share Issuance
- Hinge Health issued 8.5 million shares in its Initial Public Offering (IPO) in May 2025.
- The IPO was priced at $32 per share, raising $437 million for the company.
- A total of 13.7 million shares were part of the IPO, including 5.2 million shares sold by existing shareholders.
Inbound Investments
- In October 2021, Hinge Health secured $400 million in Series E financing, achieving a valuation of $6.2 billion.
- Prior to that, in January 2021, the company completed a $300 million Series D funding round, which valued the company at $3 billion.
- Over $1 billion had been invested in Hinge Health by October 2021, supporting the development of its clinical, data science, and R&D teams.
Outbound Investments
- Hinge Health has made acquisitions, including wrnch and Enso Relief.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Hinge Health Stock (+17%): Earnings Beat & AI Narrative Ignite Rally | 02/12/2026 | |
| Hinge Health Earnings Notes | 12/20/2025 | |
| Can Hinge Health Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.56 |
| Mkt Cap | 0.5 |
| Rev LTM | 392 |
| Op Inc LTM | -142 |
| FCF LTM | 57 |
| FCF 3Y Avg | -33 |
| CFO LTM | 60 |
| CFO 3Y Avg | -32 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.7% |
| Rev Chg 3Y Avg | -2.4% |
| Rev Chg Q | -12.2% |
| QoQ Delta Rev Chg LTM | -3.2% |
| Op Mgn LTM | -72.8% |
| Op Mgn 3Y Avg | -75.5% |
| QoQ Delta Op Mgn LTM | 2.1% |
| CFO/Rev LTM | -7.4% |
| CFO/Rev 3Y Avg | -44.6% |
| FCF/Rev LTM | -10.5% |
| FCF/Rev 3Y Avg | -48.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 0.9 |
| P/EBIT | -2.2 |
| P/E | -2.3 |
| P/CFO | 0.7 |
| Total Yield | -67.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -82.6% |
| D/E | 0.5 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.0% |
| 3M Rtn | -2.5% |
| 6M Rtn | -29.3% |
| 12M Rtn | -35.9% |
| 3Y Rtn | -86.8% |
| 1M Excs Rtn | -4.3% |
| 3M Excs Rtn | -3.9% |
| 6M Excs Rtn | -34.5% |
| 12M Excs Rtn | -43.9% |
| 3Y Excs Rtn | -153.3% |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/10/2026 | |||
| 11/4/2025 | -15.1% | -17.1% | -6.4% |
| 8/5/2025 | 25.6% | 16.1% | 16.2% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 1 | 1 | 1 |
| Median Positive | 25.6% | 16.1% | 16.2% |
| Median Negative | -15.1% | -17.1% | -6.4% |
| Max Positive | 25.6% | 16.1% | 16.2% |
| Max Negative | -15.1% | -17.1% | -6.4% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Perez, Daniel Antonio | CEO & Co-Founder | Direct | Sell | 1062026 | 46.38 | 166,665 | Form | ||
| 2 | Pursley, James | President | Direct | Sell | 12232025 | 48.40 | 15,000 | 725,950 | 37,254,715 | Form |
| 3 | Budge, James | Chief Financial Officer | Direct | Sell | 12232025 | 48.41 | 10,491 | 507,837 | 21,355,866 | Form |
| 4 | Perez, Daniel Antonio | CEO & Co-Founder | Direct | Sell | 12162025 | 48.53 | 166,670 | Form | ||
| 5 | Robinson, Elliott | See footnote | Sell | 12092025 | 0.00 | 0 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.